259 related articles for article (PubMed ID: 20604735)
1. Isolated limb infusion with melphalan and actinomycin D in melanoma patients: factors predictive of acute regional toxicity.
Kam PC; Thompson JF
Expert Opin Drug Metab Toxicol; 2010 Sep; 6(9):1039-45. PubMed ID: 20604735
[TBL] [Abstract][Full Text] [Related]
2. Factors predictive of acute regional toxicity after isolated limb infusion with melphalan and actinomycin D in melanoma patients.
Kroon HM; Moncrieff M; Kam PC; Thompson JF
Ann Surg Oncol; 2009 May; 16(5):1184-92. PubMed ID: 19224289
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of repeat isolated limb infusion with melphalan and actinomycin D for recurrent melanoma.
Kroon HM; Lin DY; Kam PC; Thompson JF
Cancer; 2009 May; 115(9):1932-40. PubMed ID: 19288571
[TBL] [Abstract][Full Text] [Related]
4. Outcomes following isolated limb infusion for melanoma. A 14-year experience.
Kroon HM; Moncrieff M; Kam PC; Thompson JF
Ann Surg Oncol; 2008 Nov; 15(11):3003-13. PubMed ID: 18509706
[TBL] [Abstract][Full Text] [Related]
5. Isolated limb infusion for in-transit malignant melanoma of the extremity: a well-tolerated but less effective alternative to hyperthermic isolated limb perfusion.
Beasley GM; Petersen RP; Yoo J; McMahon N; Aloia T; Petros W; Sanders G; Cheng TY; Pruitt SK; Seigler H; Tyler DS
Ann Surg Oncol; 2008 Aug; 15(8):2195-205. PubMed ID: 18528730
[TBL] [Abstract][Full Text] [Related]
6. Isolated limb infusion as palliative treatment for advanced limb disease in patients with AJCC stage IV melanoma.
Kroon HM; Lin DY; Kam PC; Thompson JF
Ann Surg Oncol; 2009 May; 16(5):1193-201. PubMed ID: 19224288
[TBL] [Abstract][Full Text] [Related]
7. Isolated limb infusion with melphalan and dactinomycin for regional melanoma and soft-tissue sarcoma of the extremity: final report of a phase II clinical trial.
Brady MS; Brown K; Patel A; Fisher C; Marx W
Melanoma Res; 2009 Apr; 19(2):106-11. PubMed ID: 19282789
[TBL] [Abstract][Full Text] [Related]
8. A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US.
Beasley GM; Caudle A; Petersen RP; McMahon NS; Padussis J; Mosca PJ; Zager JS; Hochwald SN; Grobmyer SR; Delman KA; Andtbacka RH; Noyes RD; Kane JM; Seigler H; Pruitt SK; Ross MI; Tyler DS
J Am Coll Surg; 2009 May; 208(5):706-15; discussion 715-7. PubMed ID: 19476821
[TBL] [Abstract][Full Text] [Related]
9. Does increased experience with isolated limb infusion for advanced limb melanoma influence outcome? A comparison of two treatment periods at a single institution.
Huismans AM; Kroon HM; Kam PC; Thompson JF
Ann Surg Oncol; 2011 Jul; 18(7):1877-83. PubMed ID: 21499810
[TBL] [Abstract][Full Text] [Related]
10. Use of an automated circuit for isolated limb infusion for malignancy.
Grobmyer SR; Filichia L; Robinson AR; Clark TD; Vaughn K; Copeland EM; Hochwald SN
Eur J Surg Oncol; 2010 Dec; 36(12):1215-9. PubMed ID: 20947288
[TBL] [Abstract][Full Text] [Related]
11. Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor- alpha versus toxicity after melphalan alone.
Vrouenraets BC; Eggermont AM; Hart AA; Klaase JM; van Geel AN; Nieweg OE; Kroon BB
Eur J Surg Oncol; 2001 Jun; 27(4):390-5. PubMed ID: 11417986
[TBL] [Abstract][Full Text] [Related]
12. Isolated limb infusion for melanoma: a simple alternative to isolated limb perfusion.
Mian R; Henderson MA; Speakman D; Finkelde D; Ainslie J; McKenzie A
Can J Surg; 2001 Jun; 44(3):189-92. PubMed ID: 11407828
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of isolated limb infusion with cytotoxic drugs in elderly patients with advanced locoregional melanoma.
Kroon HM; Lin DY; Kam PC; Thompson JF
Ann Surg; 2009 Jun; 249(6):1008-13. PubMed ID: 19474677
[TBL] [Abstract][Full Text] [Related]
14. A phase II trial of isolated limb infusion with melphalan and dactinomycin for regional melanoma and soft tissue sarcoma of the extremity.
Brady MS; Brown K; Patel A; Fisher C; Marx W
Ann Surg Oncol; 2006 Aug; 13(8):1123-9. PubMed ID: 16791448
[TBL] [Abstract][Full Text] [Related]
15. Repeat isolated limb perfusion with melphalan for recurrent melanoma of the limbs.
Klop WM; Vrouenraets BC; van Geel BN; Eggermont AM; Klaase JM; Nieweg OE; Kroon BB
J Am Coll Surg; 1996 Jun; 182(6):467-72. PubMed ID: 8646345
[TBL] [Abstract][Full Text] [Related]
16. Isolated limb infusion for malignant melanoma: predictors of response and outcome.
Barbour AP; Thomas J; Suffolk J; Beller E; Smithers BM
Ann Surg Oncol; 2009 Dec; 16(12):3463-72. PubMed ID: 19830498
[TBL] [Abstract][Full Text] [Related]
17. Hyperthermic isolated limb perfusion (HILP) in malignant melanoma. Experience with 101 patients.
Knorr C; Meyer T; Janssen T; Goehl J; Hohenberger W
Eur J Surg Oncol; 2006 Mar; 32(2):224-7. PubMed ID: 16289716
[TBL] [Abstract][Full Text] [Related]
18. Isolated limb infusion for melanoma: a less morbid alternative to hyperthermic isolated limb perfusion in the US.
Santillan AA; Zager JS
Expert Opin Drug Metab Toxicol; 2010 Sep; 6(9):1033-7. PubMed ID: 20078252
[No Abstract] [Full Text] [Related]
19. Predictive factors of regional toxicity and serum creatine phosphokinase levels after isolated limb infusion for melanoma: a multi-institutional analysis.
Santillan AA; Delman KA; Beasley GM; Mosca PJ; Hochwald SN; Grobmyer SR; Andtbacka RH; Noyes RD; Kane JM; Ross MI; Tyler DS; Zager JS
Ann Surg Oncol; 2009 Sep; 16(9):2570-8. PubMed ID: 19543771
[TBL] [Abstract][Full Text] [Related]
20. Hyperthermic antiblastic perfusion with TNFalpha and melphalan in stage III limb melanoma patients: A phase I - II SITILO study.
Di Filippo F; Rossi CR; Garinei R; Anzà M; Cavaliere F; Botti C; Perri P; Di Filippo S; Di Angelo P; Principi F; Laurenzi L
J Exp Clin Cancer Res; 2003 Dec; 22(4 Suppl):97-101. PubMed ID: 16767914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
